Negative / Null Result ReportOpen accessMedicine· cited by 19

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial

Graham Jackson; Charlotte Pawlyn; David A. Cairns; Alina Striha; Corinne Collett; Anna Waterhouse; John R Jones; Jamie Wilson · 2020 · British Journal of Haematology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Second-generation immunomodulatory agents, such as lenalidomide, have a more favourable side-effect profile than the first-generation thalidomide, but their optimum combination and duration for patients with newly diagnosed transplant-ineligible myeloma (ND-TNE-MM) has not been defined. The most appropriate delivery and dosing regimens of these therapies for patients at advanced age and frailty status is also unclear. The Myeloma XI study compared cyclophosphamide, thalidomide and dexamethasone (CTDa) to cyclophosphamide, lenalidomide and dexamethasone (CRDa) as induction therapy, followed by

Abstract by Graham Jackson; Charlotte Pawlyn; David A. Cairns; Alina Striha; Corinne Collett; Anna Waterhouse; John R Jones; Jamie Wilson, British Journal of Haematology (2020) — licensed CC BY 4.0.

Read the full paper (open access)